
Emmanuel J. Favaloro, PhD, FFSc (RCPA)\(^1\)

\(^1\) Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia


Welcome to the start of yet another year with *Seminars in Thrombosis & Hemostasis* (STH). This is my 8th year as the Editor-in-Chief, and my 11th year of editorial association with this journal, having originally served as a Regional Editor.

First, I sincerely wish to thank all the contributors to STH over the past years, as well as the Guest Editors for these issues, and of course the current and past Senior and Associate Editors of the journal. There have been several changes to the editorial team. We have two new Senior Editors: Ton Lisman joins Marcel Levi as a second European Senior Editor, and Sam Schulman, a long-time Associate Editor of STH, joins Hau Kwaan as a second North American Senior Editor. We have also increased the ranks of Associate Editors, with the aim to have around 10 to 12 contributing issues from each of the “global regions” of America, Europe, and Asia-Pacific.

I will also take this opportunity to thank the journal production team at Thieme Medical Publishers for their high production standards and for facilitating both the print and online issues of the journal. In particular, I would like to thank Subhankar De, the Production Editor for STH who now leads the production team. I also wish to thank Kelly Coffey, a Journals Coordinator for Thieme Medical Publishers, as well as other key people at Thieme, some of whom prefer to remain unnamed, for the additional support provided over recent years.

This is also the time that we reflect on our journal’s impact factor, which for 2014 was 3.876, which represents a small rise from our 2013 impact factor of 3.693 (Fig. 1). I am hopeful that this reflects a stabilization of the STH impact factor at around 4 over the coming years. In any case, the impact factor is not the only marker of journal “quality” that we should consider, given the existence of other biometric markers and the limitations of any individual marker (including the impact factor) as a “quality” indicator.\(^1,2\)

As I also now do annually, the highest cited (2012/2013-published) contributions\(^3–43\) from this journal are listed in Table 1 for the potential interest of the readership and contributing authors. These contributions identify those publications, most contributing to the 2014 impact factor, and each have now been cited 15 or more times in literature, with the top 11-listed articles having been cited 25 or more times. For those interested, the current listing can be compared with those of the most recently published top downloaded article listings from STH, the basis of the Eberhard F. Mammen “most popular” awards.\(^44,45\)

Accordingly, I would like to thank all the contributors, guest editors, and the editorial team for bringing us the content that makes STH.

Finally, a short note to confirm that, as always, we will continue to develop plans for the future content of this journal, and we are confident that we will be able to continue to bring its readers the high-quality journal that is expected from us. Currently confirmed topics for issues that we plan to publish over the next 12 or so months are listed in Table 2.

### Table 1

<table>
<thead>
<tr>
<th>Year</th>
<th>Impact Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>1.56</td>
</tr>
<tr>
<td>2004</td>
<td>2.01</td>
</tr>
<tr>
<td>2005</td>
<td>2.73</td>
</tr>
<tr>
<td>2006</td>
<td>3.00</td>
</tr>
<tr>
<td>2007</td>
<td>3.21</td>
</tr>
<tr>
<td>2008</td>
<td>4.00</td>
</tr>
<tr>
<td>2009</td>
<td>4.16</td>
</tr>
<tr>
<td>2010</td>
<td>4.57</td>
</tr>
<tr>
<td>2011</td>
<td>4.21</td>
</tr>
<tr>
<td>2012</td>
<td>4.26</td>
</tr>
<tr>
<td>2013</td>
<td>4.52</td>
</tr>
<tr>
<td>2014</td>
<td>5.00</td>
</tr>
</tbody>
</table>

**Fig. 1** The impact factor for *Seminars in Thrombosis & Hemostasis*, from 2003 to 2014.

---

**Address for correspondence**

Dr. E. J. Favaloro, FFSc (RCPA), Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW 2145, Australia (e-mail: emmanuel.favaloro@health.nsw.gov.au).

**Issue Theme Editorial**

Compilation I; Guest Editors: Emmanuel J. Favaloro, PhD, FFSc (RCPA), and Giuseppe Lippi, MD.

**Copyright © 2016 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.**

Tel: +1(212) 584-4662.


**ISSN** 0094-6176.
Table 1 Most highly cited, 2012/2013 published, contributions from *Seminars in Thrombosis & Hemostasis*

<table>
<thead>
<tr>
<th>No.</th>
<th>Authors</th>
<th>Title</th>
<th>Journal</th>
<th>Volume</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Willis R, Harris EN, Pierangeli SS.</td>
<td>Pathogenesis of the antiphospholipid syndrome.</td>
<td>Semin Thromb Hemost</td>
<td>38(4)</td>
<td>375–384</td>
</tr>
<tr>
<td>7</td>
<td>Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A.</td>
<td>What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?</td>
<td>Semin Thromb Hemost</td>
<td>38(4)</td>
<td>322–327</td>
</tr>
<tr>
<td>9</td>
<td>Aatonen M, Grönholm M, Siljander PR.</td>
<td>Platelet-derived microvesicles: multitalented participants in intercellular communication.</td>
<td>Semin Thromb Hemost</td>
<td>38(1)</td>
<td>102–113</td>
</tr>
<tr>
<td>13</td>
<td>Lippi G, Plebani M, Favaloro EJ.</td>
<td>Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia.</td>
<td>Semin Thromb Hemost</td>
<td>39(3)</td>
<td>258–266</td>
</tr>
<tr>
<td>24</td>
<td>Tripodi A.</td>
<td>To mix or not to mix in lupus anticoagulant testing? That is the question.</td>
<td>Semin Thromb Hemost</td>
<td>2012;38(4)</td>
<td>385–389</td>
</tr>
</tbody>
</table>
At the same time, we recognize the need to retain some flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises. We look forward to another interesting year of reading in 2016.

References
Table 1 (Continued)


Table 2 The current planned topics for future issues of Seminars in Thrombosis & Hemostasis include

- Editorial compilations (continuing series)
- At the crossroads of transfusion medicine and hemostasis
- Platelet function in thrombosis and hemostasis
- Controversies in inherited bleeding disorders
- The role of fibrinogen and factor XIII in hemostasis, and the identification and treatment of associated disorders
- Thrombosis & hemostasis in women and during pregnancy
- Laboratory assessment and monitoring of therapy in thrombosis and bleeding disorders
- Fibrinolysis
- Antiphospholipid antibodies and the antiphospholipid syndrome

At the same time, we recognize the need to retain some flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises. We look forward to another interesting year of reading in 2016.

References


Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 2012;38(4):385–389


Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 2012;38(4):382–391


